How to Get Farxiga in Louisiana

What Is Farxiga and Why Do Louisiana Patients Seek It?

Dapagliflozin (Farxiga) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by AstraZeneca. The FDA has approved it for three separate indications: type 2 diabetes mellitus, heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD) in adults at risk of progression. Its once-daily oral dosing and well-characterized safety profile have made it one of the most prescribed SGLT2 inhibitors in the United States.

The landmark DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg once daily reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo in patients with HFrEF, regardless of whether they had diabetes [1]. That trial result reshaped cardiology guidelines and created a large population of non-diabetic heart failure patients who now need this drug. In Louisiana, where age-adjusted cardiovascular disease mortality runs roughly 20% above the national average according to CDC data [2], the demand for Farxiga across all three indications is substantial.

Louisiana's telehealth prescribing framework, updated following the post-pandemic regulatory environment, allows licensed clinicians to prescribe schedule-exempt drugs like dapagliflozin after a synchronous audio-visual encounter. That change opened access for patients in Shreveport, Baton Rouge, Lafayette, and rural parishes who previously had limited specialist availability.

Who Can Prescribe Farxiga in Louisiana?

Any Louisiana-licensed prescriber with prescriptive authority may write for dapagliflozin. That group includes medical doctors (MDs), doctors of osteopathic medicine (DOs), nurse practitioners (NPs), and physician assistants (PAs). Dapagliflozin is not a controlled substance, so no DEA registration or state CDS permit is required beyond a standard Louisiana controlled substances license, and the drug itself does not require one at all.

Nurse practitioners in Louisiana hold full practice authority under La. R.S. 37:913, meaning they do not need a collaborating physician signature on a Farxiga prescription. PAs require a supervising physician relationship but may independently generate written prescriptions. Either can conduct a telehealth visit and transmit an electronic prescription directly to your preferred Louisiana pharmacy or a mail-order pharmacy licensed to ship into the state.

Out-of-state telehealth platforms that employ clinicians holding a Louisiana license, or clinicians registered under the Louisiana State Board of Medical Examiners' telemedicine provisions, are also permitted to prescribe. Platforms operating under the Interstate Medical Licensure Compact (IMLC) with a Louisiana license on file satisfy this requirement.

The table below outlines the three prescriber pathways Louisiana patients most commonly use.

Pathway 1: In-person primary care or endocrinology visit. The clinician reviews labs drawn the same day or within the prior 90 days, confirms indication, and writes the prescription electronically. Same-day dispensing is achievable at most Louisiana retail pharmacies.

Pathway 2: Louisiana-licensed telehealth platform. An audio-visual encounter, usually 15 to 20 minutes, is scheduled online. The clinician reviews uploaded or electronically accessed lab results and writes the prescription within 24 hours of the visit. The prescription is sent to a pharmacy of your choice.

Pathway 3: HealthRX telehealth. Our clinicians are licensed in Louisiana and can evaluate patients for dapagliflozin across all three FDA-approved indications. After reviewing your labs and medical history, a clinician can transmit a prescription to a local pharmacy or arrange mail-order delivery.

What Labs Do You Need Before Getting Farxiga in Louisiana?

Your prescribing clinician will need a current metabolic panel before writing for dapagliflozin. These are not optional courtesy tests. The FDA-approved label specifies that dapagliflozin should not be initiated in patients with an eGFR <25 mL/min/1.73 m² for the CKD indication, and efficacy for glycemic control is reduced when eGFR falls <45 mL/min/1.73 m² [3].

The standard pre-treatment laboratory panel includes:

• eGFR and serum creatinine. Kidney function determines both dosing and whether the drug is appropriate at all.
• BMP (basic metabolic panel). Screens for electrolyte abnormalities, particularly relevant because SGLT2 inhibitors carry a small risk of euglycemic diabetic ketoacidosis.
• HbA1c. Required for the type 2 diabetes indication to document baseline glycemic status and confirm the diagnosis.
• Urinary albumin-to-creatinine ratio (UACR). The DAPA-CKD trial (N=4,304) used UACR 200 to 5 to 000 mg/g as an enrollment criterion [4]. For CKD patients, a UACR confirms proteinuria staging and satisfies prior authorization requirements under most Louisiana commercial plans.
• Urinalysis with culture (if symptomatic). SGLT2 inhibitors increase the risk of urinary tract infections. Active UTI should be treated before starting the drug.

Most Louisiana commercial labs (Quest Diagnostics and Labcorp both operate extensively across the state) can return a standard BMP and HbA1c within 24 to 48 hours. If you use a telehealth platform, you will typically receive a lab requisition at the time of booking, allowing results to be ready by the time your video visit occurs.

How Prior Authorization Works for Farxiga in Louisiana

The majority of Louisiana commercial health insurance plans require prior authorization (PA) for Farxiga. The documentation your prescriber will submit generally includes the following elements.

For the type 2 diabetes indication: a documented HbA1c at or above 7.0%, confirmation that the patient has trialed metformin (or has a documented contraindication to it), and chart notes supporting the diagnosis of type 2 diabetes for at least 90 days.

For the heart failure indication: an echocardiogram or imaging report confirming reduced ejection fraction (typically defined as LVEF <40%), documentation of current guideline-directed medical therapy (ACE inhibitor or ARB, beta-blocker), and a diagnosis of HFrEF per ICD-10 code I50.20 or I50.22.

For the CKD indication: eGFR between 25 and 75 mL/min/1.73 m², UACR at or above 200 mg/g, and confirmation the patient is on a maximally tolerated dose of an ACE inhibitor or ARB.

The 2022 American Diabetes Association Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with proven benefit is recommended as part of the glucose-lowering regimen independent of baseline HbA1c" [5]. This language is often cited in PA appeal letters when an initial request is denied.

Most Louisiana commercial plans render a PA decision within 3 to 5 business days. Your prescriber can request peer-to-peer review if the initial decision is adverse. Turnaround after a successful peer-to-peer review is usually 24 to 48 hours.

Louisiana Medicaid Coverage for Farxiga

Louisiana Medicaid (Healthy Louisiana) does not cover Farxiga as of January 2025. The state's preferred drug list includes other SGLT2 inhibitors for narrow indications, but brand-name dapagliflozin is excluded. This affects a meaningful share of the Louisiana population: approximately 1.9 million residents are enrolled in Medicaid [6].

Patients on Louisiana Medicaid who need dapagliflozin have several options.

AstraZeneca patient assistance. The AstraZeneca AZ&Me Prescription Savings Program provides Farxiga at no cost to qualifying patients with household incomes at or below 400% of the federal poverty level and no other prescription coverage. Enrollment can be completed online or through your prescriber's office.

Copay card (commercially insured patients). AstraZeneca's Farxiga copay card reduces out-of-pocket costs to as little as $0 per month for eligible commercially insured patients. It cannot be used with federal or state government insurance, including Louisiana Medicaid or Medicare Part D.

Cash-pay pricing. The average retail price for a 30-tablet supply of Farxiga 10 mg in Baton Rouge runs approximately $550 to $600 without insurance as of early 2025. GoodRx and similar discount programs may reduce this to $400 to $480 at select Louisiana pharmacies. A clinician at HealthRX can advise on the most cost-effective pharmacy for your zip code.

Telehealth Prescribing for Farxiga in Louisiana: Step-by-Step

Getting Farxiga through a Louisiana telehealth provider follows a predictable sequence. The steps below apply whether you use HealthRX or another licensed platform.

Step 1: Request a lab requisition. Most telehealth platforms send a lab order before your appointment so results are available during the visit. Order the panel listed in the "labs" section above.

Step 2: Complete your intake form. You will document current medications, allergies, and your medical history relevant to diabetes, heart failure, or CKD. Uploading recent chart notes, prior echocardiograms, or nephrology records shortens the visit significantly.

Step 3: Attend a synchronous audio-visual visit. Louisiana law requires a real-time video encounter for a new telehealth relationship. The visit typically runs 15 to 25 minutes. Your clinician will confirm the indication, review labs, discuss risks (genital mycotic infections affect roughly 6 to 8% of female patients; euglycemic DKA is rare but requires hydration counseling), and determine the appropriate starting dose.

Step 4: Receive an electronic prescription. For dapagliflozin, the starting dose is 10 mg once daily for all approved indications. Your clinician will send the prescription to your preferred pharmacy via electronic prescribing. There is no DEA number requirement for this drug.

Step 5: Pharmacy dispensing. Louisiana retail pharmacies, including CVS, Walgreens, Walmart Pharmacy, and independent pharmacies, all stock Farxiga. Mail-order pharmacies licensed in Louisiana (Express Scripts, OptumRx, and specialty mail-order services) can ship to any Louisiana address within 2 to 5 business days.

From the time of your video visit to the time you pick up your first prescription, 24 to 72 hours is the typical window for telehealth patients. In-person visits that include same-day labs may compress this to a single afternoon.

503A Pharmacies and Dapagliflozin in Louisiana

Louisiana has a functioning network of 503A compounding pharmacies licensed by the Louisiana Board of Pharmacy. A 503A pharmacy compounds medications for individual patients based on a valid prescriber order. They may prepare dapagliflozin in alternative dose forms if a specific clinical need justifies it, though the FDA-approved commercial tablet is the standard of care and the preferred dispensing route for most patients.

For patients who need dose adjustments outside the commercially available strengths (5 mg and 10 mg tablets), or who have a documented allergy to an excipient in the commercial formulation, a 503A pharmacy can be an appropriate alternative. The prescriber must include documentation of medical necessity on the compound order. As the FDA notes in its compounding guidance, 503A pharmacies may not compound drugs that are essentially copies of commercially available products without a specific documented reason [7].

Compounded dapagliflozin from a Louisiana 503A pharmacy is not covered by insurance or Louisiana Medicaid. Cash pricing varies by pharmacy and dose form.

Transferring an Existing Farxiga Prescription to Louisiana

If you are relocating to Louisiana from another state and already take Farxiga, transferring your prescription is straightforward. Louisiana pharmacy law allows a one-time transfer of a non-controlled substance prescription between licensed pharmacies in different states. Present your existing prescription bottle and the contact information for your previous pharmacy to any Louisiana retail pharmacy. The receiving pharmacist contacts the dispensing pharmacy directly to verify and transfer the remaining refills.

For mail-order prescriptions through a national PBM (Express Scripts, CVS Caremark, OptumRx), your plan's coverage follows you to Louisiana. Update your delivery address through your online account or by calling member services.

If your out-of-state prescriber is not licensed in Louisiana and you need a new prescription (because refills have run out), you will need a Louisiana-licensed prescriber to write a new order. A telehealth visit is the fastest way to accomplish this. Most platforms can schedule within 24 to 48 hours and have labs reviewed before the appointment.

Dosing, Side Effects, and Monitoring During Treatment

Farxiga is initiated at 10 mg once daily for all three approved indications. For type 2 diabetes, the dose may remain at 5 mg once daily if tolerability is a concern, though the 10 mg dose provides greater glycemic effect. The dose is not adjusted for mild to moderate hepatic impairment but should not be initiated below eGFR 25 mL/min/1.73 m².

Common side effects your Louisiana prescriber will discuss before starting:

• Genital mycotic infections. Occur in approximately 6 to 8% of women and 3 to 4% of men due to glucosuria. Treatment with a topical antifungal is usually sufficient.
• Urinary tract infections. Pooled trial data show a modest increase in UTI frequency [8]. Patients with recurrent UTIs may require a risk-benefit discussion.
• Volume depletion and hypotension. Particularly relevant in elderly patients or those on loop diuretics. Your prescriber may reduce diuretic doses before starting dapagliflozin.
• Euglycemic diabetic ketoacidosis. Rare but serious. Patients should hold dapagliflozin 3 days before elective surgery and during prolonged fasting or severe illness.
• Lower-limb amputation risk. Associated primarily with canagliflozin; the DAPA-HF and DECLARE-TIMI 58 trials did not show a statistically significant amputation signal for dapagliflozin [9].

Follow-up labs at 4 weeks after initiation should include a repeat BMP and eGFR. An initial decrease in eGFR of 3 to 5 mL/min/1.73 m² is expected and does not indicate worsening kidney disease. This hemodynamic effect reverses upon drug discontinuation and is distinct from the longer-term kidney-protective effect documented in DAPA-CKD, where dapagliflozin reduced the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal or cardiovascular death by 39% versus placebo [4].

The American Heart Association's 2022 heart failure guidelines state: "SGLT2 inhibitors are recommended for patients with symptomatic chronic HFrEF to reduce hospitalization for HF and cardiovascular mortality, irrespective of the presence of type 2 diabetes" [10].